Year |
Citation |
Score |
2023 |
Saleiro D, Kosciuczuk EM, Fischietti M, Perez RE, Yang GS, Eckerdt F, Beauchamp EM, Hou Y, Wang Q, Weinberg RS, Fish EN, Yue F, Hoffman R, Platanias LC. Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells. Cancer Research Communications. 3: 943-951. PMID 37377894 DOI: 10.1158/2767-9764.CRC-23-0010 |
0.354 |
|
2022 |
Fischietti M, Eckerdt F, Perez RE, Guillen Magaña JN, Mazewski C, Ho S, Gonzalez C, Streich LD, Beauchamp EM, Heimberger AB, Baran AH, Yue F, James CD, Platanias LC. SLFN11 negatively regulates non-canonical NFkB signaling to promote glioblastoma progression. Cancer Research Communications. 2: 966-978. PMID 36382088 DOI: 10.1158/2767-9764.crc-22-0192 |
0.367 |
|
2021 |
Suarez M, Blyth GT, Mina AA, Kosciuczuk EM, Dolniak B, Dinner S, Altman JK, Eklund EA, Saleiro D, Beauchamp EM, Platanias LC. Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget. 12: 955-966. PMID 34012509 DOI: 10.18632/oncotarget.27952 |
0.304 |
|
2021 |
Fischietti M, Eckerdt F, Blyth GT, Arslan AD, Mati WM, Oku CV, Perez RE, Lee-Chang C, Kosciuczuk EM, Saleiro D, Beauchamp EM, Lesniak MS, Verzella D, Sun L, Fish EN, et al. Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene. PMID 33846574 DOI: 10.1038/s41388-021-01761-1 |
0.355 |
|
2021 |
Eisfelder BJ, Saygin C, Wynne J, Colton MW, Fischietti M, Beauchamp EM, Cheng JX, Odenike O, Roboz G, Alachkar H, Stock W. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer Journal. 11: 48. PMID 33658483 DOI: 10.1038/s41408-021-00433-3 |
0.31 |
|
2019 |
Kosciuczuk EM, Kar AK, Blyth GT, Fischietti M, Abedin S, Mina AA, Siliezar R, Rzymski T, Brzozka K, Eklund EA, Beauchamp EM, Eckerdt F, Saleiro D, Platanias LC. Inhibitory effects of SEL201 in acute myeloid leukemia. Oncotarget. 10: 7112-7121. PMID 31903169 DOI: 10.18632/Oncotarget.27388 |
0.35 |
|
2019 |
Eckerdt F, Clymer J, Bell JB, Beauchamp EM, Blyth GT, Goldman S, Platanias LC. Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma. Scientific Reports. 9: 12822. PMID 31492956 DOI: 10.1038/S41598-019-49299-3 |
0.417 |
|
2019 |
Eckerdt F, Bell JB, Beauchamp EM, Clymer J, Blyth GT, Kosciuczuk EM, Ma Q, Chen DZ, Horbinski C, Goldman S, Munshi HG, Hashizume R, Platanias LC. Potent Antineoplastic Effects of Combined PI3Kα-MNK Inhibition in Medulloblastoma. Molecular Cancer Research : McR. PMID 30842251 DOI: 10.1158/1541-7786.Mcr-18-1193 |
0.428 |
|
2018 |
Beauchamp EM, Abedin SM, Radecki SG, Fischietti M, Arslan AD, Blyth GT, Yang A, Lantz C, Nelson A, Goo YA, Akpan I, Eklund EA, Frankfurt O, Fish EN, Thomas PM, et al. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Blood. PMID 30587525 DOI: 10.1182/Blood-2018-08-870089 |
0.302 |
|
2017 |
Bell JB, Eckerdt F, Dhruv H, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp E, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, et al. Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy is Regulated by MNK1 and mRNA Translation. Molecular Cancer Research : McR. PMID 29042487 DOI: 10.1158/1541-7786.Mcr-17-0397 |
0.334 |
|
2015 |
Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Acs Chemical Biology. PMID 26390252 DOI: 10.1021/Acschembio.5B00655 |
0.341 |
|
2015 |
Xu C, Buczkowski KA, Zhang Y, Asahina H, Beauchamp EM, Terai H, Li YY, Meyerson M, Wong KK, Hammerman PS. NSCLC Driven by DDR2 Mutation is Sensitive to Dasatinib and JQ1 Combination Therapy. Molecular Cancer Therapeutics. PMID 26206333 DOI: 10.1158/1535-7163.Mct-15-0077 |
0.313 |
|
2015 |
Colamonici M, Blyth G, Saleiro D, Szilard A, Bliss-Moreau M, Giles FJ, Altman JK, Beauchamp EM, Platanias LC. Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase. Oncotarget. 6: 8062-70. PMID 25823922 DOI: 10.18632/Oncotarget.3509 |
0.306 |
|
2015 |
Beauchamp EM, Kosciuczuk EM, Serrano R, Nanavati D, Swindell EP, Viollet B, O'Halloran TV, Altman JK, Platanias LC. Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors. Molecular Cancer Therapeutics. 14: 202-12. PMID 25344585 DOI: 10.1158/1535-7163.Mct-14-0665-T |
0.309 |
|
2014 |
Eckerdt F, Beauchamp E, Bell J, Iqbal A, Su B, Fukunaga R, Lulla RR, Goldman S, Platanias LC. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget. 5: 8442-51. PMID 25193863 DOI: 10.18632/Oncotarget.2319 |
0.381 |
|
2013 |
Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer Oncogene. 32: 3923-3932. PMID 23246968 DOI: 10.1038/Onc.2012.567 |
0.341 |
|
2012 |
Beauchamp EM, Uren A. A new era for an ancient drug: arsenic trioxide and Hedgehog signaling. Vitamins and Hormones. 88: 333-54. PMID 22391311 DOI: 10.1016/B978-0-12-394622-5.00015-8 |
0.61 |
|
2012 |
Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, Toretsky JA, Khanna C, Uren A. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 31: 269-81. PMID 21706056 DOI: 10.1038/Onc.2011.245 |
0.659 |
|
2011 |
Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A. Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice. Plos One. 6: e27243. PMID 22087269 DOI: 10.1371/Journal.Pone.0027243 |
0.552 |
|
2011 |
Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. Plos One. 6: e19343. PMID 21559405 DOI: 10.1371/Journal.Pone.0019343 |
0.641 |
|
2011 |
Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. The Journal of Clinical Investigation. 121: 148-60. PMID 21183792 DOI: 10.1172/Jci42874 |
0.656 |
|
2011 |
Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A. Abstract 663: YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion Cancer Research. 71: 663-663. DOI: 10.1158/1538-7445.Am2011-663 |
0.67 |
|
2011 |
Bulut G, Hong S, Chen K, Rahim S, Kosturko GW, Beauchamp EM, Glasgow E, Toretsky JA, Khanna C, Uren A. Abstract 4505: Development of small molecules to target ezrin as anti-metastatic agents Cancer Research. 71: 4505-4505. DOI: 10.1158/1538-7445.Am2011-4505 |
0.681 |
|
2011 |
Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A. Abstract 4328: Beta-catenin accelerates human papillomavirus type16 -E7 mediated cervical carcinogenesis in transgenic mice Cancer Research. 71: 4328-4328. DOI: 10.1158/1538-7445.Am2011-4328 |
0.555 |
|
2010 |
Beauchamp EM, Rodriguez O, Albanese C, Toretsky JA, Üren A. Abstract 3409: Arsenic trioxide inhibits Ewing sarcoma growth by blocking Hedgehog/GLI pathway Cancer Research. 70: 3409-3409. DOI: 10.1158/1538-7445.Am10-3409 |
0.643 |
|
2009 |
Golestaneh N, Beauchamp E, Fallen S, Kokkinaki M, Uren A, Dym M. Wnt signaling promotes proliferation and stemness regulation of spermatogonial stem/progenitor cells. Reproduction (Cambridge, England). 138: 151-62. PMID 19419993 DOI: 10.1530/Rep-08-0510 |
0.579 |
|
2009 |
Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J, Uren A. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. The Journal of Biological Chemistry. 284: 9074-82. PMID 19189974 DOI: 10.1074/Jbc.M806233200 |
0.623 |
|
2008 |
Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA, Uren A, Rubin JS. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Molecular and Cellular Biology. 28: 2368-79. PMID 18212053 DOI: 10.1128/Mcb.01780-07 |
0.59 |
|
Show low-probability matches. |